Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells in Vitro

Rosette, C.; Rosette, N.; Mazzetti, A.; Moro, L.; Gerloni, M.

Journal of Drugs in Dermatology Jdd 18(2): 197-201

2019


ISSN/ISBN: 1545-9616
PMID: 30811143
Document Number: 17720
Cortexolone 17α-propionate (clascoterone) is a novel androgen antagonist that is currently being analyzed in a large phase 2 clinical trial for the topical treatment of androgenetic alopecia (AGA). While the pathogenesis of AGA is still debated, the consensus is that AGA is an androgen-dependent hair disorder with strong genetic links, and that the testosterone metabolite, dihydrotestosterone (DHT), plays a causal role in its development. DHT binds to the androgen receptor (AR) in scalp dermal papilla cells (DPC) to induce AR-mediated transcription of genes that contribute to AGA in genetically predisposed individuals.

Document emailed within 1 workday
Secure & encrypted payments

Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells in Vitro